肝糖原贮积症和特发性酮症性低血糖患者的连续血糖监测指标:一项单中心、回顾性、观察性研究。

IF 3.7 2区 生物学 Q2 ENDOCRINOLOGY & METABOLISM Molecular genetics and metabolism Pub Date : 2024-09-01 DOI:10.1016/j.ymgme.2024.108573
{"title":"肝糖原贮积症和特发性酮症性低血糖患者的连续血糖监测指标:一项单中心、回顾性、观察性研究。","authors":"","doi":"10.1016/j.ymgme.2024.108573","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cohort data on continuous glucose monitoring (CGM) metrics are scarce for liver glycogen storage diseases (GSDs) and idiopathic ketotic hypoglycemia (IKH). The aim of this study was to retrospectively describe CGM metrics for people with liver GSDs and IKH.</p></div><div><h3>Patients and methods</h3><p>CGM metrics (descriptive, glycemic variation and glycemic control parameters) were calculated for 47 liver GSD and 14 IKH patients, categorized in cohorts by disease subtype, age and treatment status, and compared to published age-matched CGM metrics from healthy individuals. Glycemic control was assessed as time-in-range (TIR; ≥3.9 - ≤7.8 and ≥3.9 - ≤10.0 mmol/L), time-below-range (TBR; &lt;3.0 mmol/L and ≥3.0 - ≤3.9 mmol/L), and time-above-range (TAR; &gt;7.8 and &gt;10.0 mmol/L).</p></div><div><h3>Results</h3><p>Despite all patients receiving dietary treatment, GSD cohorts displayed significantly different CGM metrics compared to healthy individuals. Decreased TIR together with increased TAR were noted in GSD I, GSD III, and GSD XI (Fanconi-Bickel syndrome) cohorts (all <em>p</em> &lt; 0.05). In addition, all GSD I cohorts showed increased TBR (all <em>p</em> &lt; 0.05). In GSD IV an increased TBR (p &lt; 0.05) and decreased TAR were noted (p &lt; 0.05). In GSD IX only increased TAR was observed (p &lt; 0.05). IKH patient cohorts, both with and without treatment, presented CGM metrics similar to healthy individuals.</p></div><div><h3>Conclusion</h3><p>Despite dietary treatment, most liver GSD cohorts do not achieve CGM metrics comparable to healthy individuals. International recommendations on the use of CGM and clinical targets for CGM metrics in liver GSD patients are warranted, both for patient care and clinical trials.</p></div>","PeriodicalId":18937,"journal":{"name":"Molecular genetics and metabolism","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096719224004578/pdfft?md5=4652934eedba1477b5d1d0c1f830c15e&pid=1-s2.0-S1096719224004578-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Continuous glucose monitoring metrics in people with liver glycogen storage disease and idiopathic ketotic hypoglycemia: A single-center, retrospective, observational study\",\"authors\":\"\",\"doi\":\"10.1016/j.ymgme.2024.108573\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Cohort data on continuous glucose monitoring (CGM) metrics are scarce for liver glycogen storage diseases (GSDs) and idiopathic ketotic hypoglycemia (IKH). The aim of this study was to retrospectively describe CGM metrics for people with liver GSDs and IKH.</p></div><div><h3>Patients and methods</h3><p>CGM metrics (descriptive, glycemic variation and glycemic control parameters) were calculated for 47 liver GSD and 14 IKH patients, categorized in cohorts by disease subtype, age and treatment status, and compared to published age-matched CGM metrics from healthy individuals. Glycemic control was assessed as time-in-range (TIR; ≥3.9 - ≤7.8 and ≥3.9 - ≤10.0 mmol/L), time-below-range (TBR; &lt;3.0 mmol/L and ≥3.0 - ≤3.9 mmol/L), and time-above-range (TAR; &gt;7.8 and &gt;10.0 mmol/L).</p></div><div><h3>Results</h3><p>Despite all patients receiving dietary treatment, GSD cohorts displayed significantly different CGM metrics compared to healthy individuals. Decreased TIR together with increased TAR were noted in GSD I, GSD III, and GSD XI (Fanconi-Bickel syndrome) cohorts (all <em>p</em> &lt; 0.05). In addition, all GSD I cohorts showed increased TBR (all <em>p</em> &lt; 0.05). In GSD IV an increased TBR (p &lt; 0.05) and decreased TAR were noted (p &lt; 0.05). In GSD IX only increased TAR was observed (p &lt; 0.05). IKH patient cohorts, both with and without treatment, presented CGM metrics similar to healthy individuals.</p></div><div><h3>Conclusion</h3><p>Despite dietary treatment, most liver GSD cohorts do not achieve CGM metrics comparable to healthy individuals. International recommendations on the use of CGM and clinical targets for CGM metrics in liver GSD patients are warranted, both for patient care and clinical trials.</p></div>\",\"PeriodicalId\":18937,\"journal\":{\"name\":\"Molecular genetics and metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1096719224004578/pdfft?md5=4652934eedba1477b5d1d0c1f830c15e&pid=1-s2.0-S1096719224004578-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular genetics and metabolism\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1096719224004578\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular genetics and metabolism","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096719224004578","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:肝糖原贮积症(GSD)和特发性酮症性低血糖(IKH)的连续血糖监测(CGM)指标的队列数据很少。本研究旨在回顾性描述肝糖原贮积症和特发性酮症低血糖症患者的 CGM 指标:对 47 名肝脏 GSD 患者和 14 名 IKH 患者的 CGM 指标(描述性、血糖变化和血糖控制参数)进行了计算,并按疾病亚型、年龄和治疗状态进行了分组,与已发表的健康人的年龄匹配 CGM 指标进行了比较。评估血糖控制情况的标准是血糖在量程内的时间(TIR;≥3.9 -≤7.8 和 ≥3.9 -≤10.0 mmol/L)、血糖在量程外的时间(TBR;7.8 和 >10.0 mmol/L):结果:尽管所有患者都接受了饮食治疗,但与健康人相比,GSD 组群的 CGM 指标有显著差异。在 GSD I、GSD III 和 GSD XI(范康尼-比克尔综合征)队列中,TIR 降低,TAR 升高(均为 p):尽管进行了饮食治疗,但大多数肝脏 GSD 队列的 CGM 指标仍无法与健康人相媲美。有必要就肝脏 GSD 患者 CGM 的使用和 CGM 指标的临床目标提出国际建议,这既适用于患者护理,也适用于临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Continuous glucose monitoring metrics in people with liver glycogen storage disease and idiopathic ketotic hypoglycemia: A single-center, retrospective, observational study

Background

Cohort data on continuous glucose monitoring (CGM) metrics are scarce for liver glycogen storage diseases (GSDs) and idiopathic ketotic hypoglycemia (IKH). The aim of this study was to retrospectively describe CGM metrics for people with liver GSDs and IKH.

Patients and methods

CGM metrics (descriptive, glycemic variation and glycemic control parameters) were calculated for 47 liver GSD and 14 IKH patients, categorized in cohorts by disease subtype, age and treatment status, and compared to published age-matched CGM metrics from healthy individuals. Glycemic control was assessed as time-in-range (TIR; ≥3.9 - ≤7.8 and ≥3.9 - ≤10.0 mmol/L), time-below-range (TBR; <3.0 mmol/L and ≥3.0 - ≤3.9 mmol/L), and time-above-range (TAR; >7.8 and >10.0 mmol/L).

Results

Despite all patients receiving dietary treatment, GSD cohorts displayed significantly different CGM metrics compared to healthy individuals. Decreased TIR together with increased TAR were noted in GSD I, GSD III, and GSD XI (Fanconi-Bickel syndrome) cohorts (all p < 0.05). In addition, all GSD I cohorts showed increased TBR (all p < 0.05). In GSD IV an increased TBR (p < 0.05) and decreased TAR were noted (p < 0.05). In GSD IX only increased TAR was observed (p < 0.05). IKH patient cohorts, both with and without treatment, presented CGM metrics similar to healthy individuals.

Conclusion

Despite dietary treatment, most liver GSD cohorts do not achieve CGM metrics comparable to healthy individuals. International recommendations on the use of CGM and clinical targets for CGM metrics in liver GSD patients are warranted, both for patient care and clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular genetics and metabolism
Molecular genetics and metabolism 生物-生化与分子生物学
CiteScore
5.90
自引率
7.90%
发文量
621
审稿时长
34 days
期刊介绍: Molecular Genetics and Metabolism contributes to the understanding of the metabolic and molecular basis of disease. This peer reviewed journal publishes articles describing investigations that use the tools of biochemical genetics and molecular genetics for studies of normal and disease states in humans and animal models.
期刊最新文献
Sensitivity of transferrin isoform analysis for PMM2-CDG Assessing carnosinase 1 activity for diagnosing congenital disorders of glycosylation Treatment of congenital disorders of glycosylation: An overview CIC variants and folinic acid-responsive seizures Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1